Hologic acquires diagnostic assays manufacturer Diagenode for $159m
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Hologic acquires diagnostic assays manufacturer Diagenode for $159m

02 Mar 2021

Hologic has acquired molecular diagnostic assays and epigenetics products manufacturer Diagenode in a deal worth approximately $159m.

Hologic acquires diagnostic assays manufacturer Diagenode for $159m
Diagenode offers CE-marked real-time PCR tests for detecting bacteria, parasites, and viruses. Credit: Belova59 / Pixabay.

Hologic has acquired molecular diagnostic assays and epigenetics products manufacturer Diagenode in a deal worth approximately $159m.

The acquisition will expand Hologic’s diagnostic business across test menu, customer segments, and geography.

Diagenode offers more than 30 CE-marked real-time polymerase chain reaction (PCR) tests for detecting bacteria, parasites, and viruses linked to sexually transmitted infections, respiratory diseases, meningitis, and gastroenteritis.

Hologic international group president Jan Verstreken said: “Acquiring Diagenode further strengthens our molecular diagnostics business by expanding our international capabilities, improving our regional time-to-market, and allowing us to offer a broader, more differentiated test menu.

“Diagenode has been a great partner since 2016, helping us develop and manufacture PCR-based assays for Panther Fusion.”

Earlier, Diagenode had partnered with Hologic in developing Panther Fusion assays for group B Streptococcus and Bordetella.

Furthermore, the company played a major role in epigenetics with a strong portfolio of devices, kits, reagents, antibodies, and services to facilitate DNA and RNA analysis.

Diagenode founder and CEO Didier Allaer said: “We are very pleased that the Diagenode team will become part of Hologic’s diagnostic business.

“Our businesses are highly complementary, and we are excited that Hologic’s commercial resources and leadership in molecular automation will enable us to offer our assay menu more broadly.”

The deal is in line with Hologic’s tuck-in M&A strategy, leverages its automation capabilities, and offers better potential for growth.

Last month, Hologic completed the $230m acquisition of Biotheranostics, which develops and sells two highly differentiated molecular diagnostic tests, Breast Cancer Index (BCI) and CancerTYPE ID (CTID), for breast and metastatic cancers respectively.

The purchase of Biotheranostics, along with the latest acquisition, will continue to expand Hologic’s base diagnostics business and expedite growth post-Covid-19.

In January, Hologic acquired biopsy site markers and localisation technologies developer SOMATEX Medical Technologies in a deal valued at approximately $64m.